X4 Pharmaceuticals (NASDAQ:XFOR) Stock Price Up 1.9% – Should You Buy?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR)’s stock price rose 1.9% during mid-day trading on Tuesday . The stock traded as high as $3.72 and last traded at $3.70. Approximately 191,744 shares traded hands during trading, a decline of 43% from the average daily volume of 335,343 shares. The stock had previously closed at $3.63.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of X4 Pharmaceuticals in a research note on Monday, December 29th. Stifel Nicolaus set a $10.00 target price on shares of X4 Pharmaceuticals and gave the stock a “buy” rating in a report on Friday, December 5th. Zacks Research lowered shares of X4 Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 26th. Finally, Wall Street Zen cut shares of X4 Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Sunday, November 30th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus price target of $34.50.

X4 Pharmaceuticals Trading Up 1.9%

The company’s 50 day simple moving average is $3.82 and its 200-day simple moving average is $3.30. The firm has a market cap of $323.53 million, a P/E ratio of -0.37 and a beta of 0.41. The company has a quick ratio of 5.48, a current ratio of 5.65 and a debt-to-equity ratio of 1.23.

X4 Pharmaceuticals (NASDAQ:XFOR) last issued its quarterly earnings results on Wednesday, November 5th. The company reported ($0.69) earnings per share for the quarter, topping the consensus estimate of ($0.79) by $0.10. X4 Pharmaceuticals had a negative return on equity of 343.67% and a negative net margin of 279.86%.The firm had revenue of $1.77 million for the quarter, compared to the consensus estimate of $2.05 million. As a group, research analysts predict that X4 Pharmaceuticals, Inc. will post -0.68 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in XFOR. Nantahala Capital Management LLC bought a new stake in X4 Pharmaceuticals during the 3rd quarter valued at about $7,621,000. Rosalind Advisors Inc. bought a new stake in shares of X4 Pharmaceuticals during the third quarter valued at approximately $5,283,000. Deep Track Capital LP purchased a new stake in shares of X4 Pharmaceuticals in the third quarter valued at approximately $3,839,000. Kingdon Capital Management L.L.C. boosted its holdings in shares of X4 Pharmaceuticals by 300.0% in the third quarter. Kingdon Capital Management L.L.C. now owns 933,332 shares of the company’s stock valued at $3,192,000 after purchasing an additional 700,000 shares during the period. Finally, Vanguard Group Inc. grew its stake in X4 Pharmaceuticals by 77.0% in the third quarter. Vanguard Group Inc. now owns 410,485 shares of the company’s stock worth $1,404,000 after purchasing an additional 178,593 shares in the last quarter. 72.03% of the stock is currently owned by institutional investors.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the C-X-C chemokine receptor type 4 (CXCR4) for the treatment of rare immunological diseases and oncology indications. The company’s lead asset, mavorixafor, is an orally administered, selective small-molecule CXCR4 antagonist designed to mobilize white blood cells and enhance immune function, with a primary focus on WHIM syndrome, a rare congenital immunodeficiency.

Beyond its WHIM syndrome program, X4 is advancing mavorixafor in clinical trials for additional hematologic and solid tumor settings—such as Waldenström’s macroglobulinemia and chronic lymphocytic leukemia—where modulation of the CXCR4 pathway may improve patient outcomes.